Cargando…
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant threats, none of the available therapies have been shown to consistently reduce mortality or improve patient outcomes in cl...
Autores principales: | Shields, Ryan K, Paterson, David L, Tamma, Pranita D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150276/ https://www.ncbi.nlm.nih.gov/pubmed/37125467 http://dx.doi.org/10.1093/cid/ciad094 |
Ejemplares similares
-
Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex
por: Castanheira, Mariana, et al.
Publicado: (2023) -
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023) -
Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023) -
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2023) -
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial
por: Watkins, Richard R, et al.
Publicado: (2023)